Thus, TXNIP is necessary for imatinib suppressive effect on CML cell growth, and the blockage of TXNIP expression results in the increased CML cell survival and compromises imatinib effect. This evidence concerns the gene TXNIP and chronic myelogenous leukemia, BCR-ABL1 positive.